Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Pfizer Inc patents


Recent patent applications related to Pfizer Inc. Pfizer Inc is listed as an Agent/Assignee. Note: Pfizer Inc may have other listings under different names/spellings. We're not affiliated with Pfizer Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pfizer Inc-related inventors


4-1bb binding molecules

The present disclosure provides isolated binding molecules that bind to human 4-1bb, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.. . ... Pfizer Inc

Tofacitinib oral sustained release dosage forms

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.. ... Pfizer Inc

Bispecific antibodies

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. ... Pfizer Inc

Rsv f protein mutants

The present disclosure relates to rsv f protein mutants, nucleic acids or vectors encoding a rsv f protein mutant, compositions comprising a rsv f protein mutant or nucleic acid, and uses of the rsv f protein mutants, nucleic acids or vectors, and compositions.. . ... Pfizer Inc

Therapeutic antibodies and their uses

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to bcma (b-cell maturation antigen) and/or cd3 (cluster of differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the bcma antibodies, compositions comprising the bcma antibodies, and methods of using the bcma antibodies and their conjugates for treating conditions associated with cells expressing bcma (e.g., cancer or autoimmune disease). ... Pfizer Inc

Btla fusion protein agonists and uses thereof

The present invention is based on the seminal discovery that btla agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind btla enhancing btla signaling the present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a btla agonist fusion protein as described herein.. ... Pfizer Inc

Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof

The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.. . ... Pfizer Inc

Glp-1 agonists and uses thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as glp-1r agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.. . ... Pfizer Inc

Pd-l1 antagonist combination treatments

The present disclosure describes combination therapies comprising an antagonist of programmed death ligand 1 receptor (pd-l1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.. . ... Pfizer Inc

Bispecific heterodimeric diabodies and uses thereof

. . Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the p-cadherin tumor cell associated antigen and the cd3 t cell antigen.. ... Pfizer Inc

Novel heterocyclic compounds as inhibitors of vanin-1 enzyme

. . . . Compounds, pharmaceutically acceptable salts thereof are disclosed wherein the compounds have the structure of formula (i) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.. ... Pfizer Inc

Immunogenic compositions and uses thereof

. . . . The invention relates to immunogenic compositions comprising a capsular polysaccharide (cp) from streptococcus agalactiae, commonly referred to as group b streptococcus (gbs), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against gbs and/or for reducing or preventing invasive gbs disease in subjects using the compositions disclosed herein. ... Pfizer Inc

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.. ... Pfizer Inc

Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

The present invention relates to new immunogenic compositions comprising conjugated streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a s. ... Pfizer Inc

04/05/18 / #20180092925

Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(adp-ribose) polymerase activity including the disease condition such as cancer.. ... Pfizer Inc

03/29/18 / #20180086736

Rorc2 inhibitors and methods of use thereof

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.. . ... Pfizer Inc

03/29/18 / #20180086731

Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

This invention relates to a crystalline form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.. . ... Pfizer Inc

03/08/18 / #20180065964

Solid forms of a selective cdk4/6 inhibitor

. . . . This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.. . ... Pfizer Inc

03/01/18 / #20180057579

Antagonist antibodies against gdf-8 and uses therefor

The disclosure provides improved neutralizing anti-gdf-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-gdf-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.. ... Pfizer Inc

03/01/18 / #20180055926

Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. ... Pfizer Inc

02/22/18 / #20180051012

Diacylglycerol acyl transferase 2 inhibitors

Compounds of formula i that inhibit the activity of the diacylglycerol acyltransferase 2 (dgat2) and their uses in the treatment of diseases linked thereto in animals are described herein.. . ... Pfizer Inc

02/15/18 / #20180042926

Diacylglycerol acyltransferase 2 inhibitors

. . Compounds of formula i that inhibit the activity of the diacylglycerol acyltransferase 2 (dgat2) and their uses in the treatment of diseases linked thereto in animals are described herein.. . ... Pfizer Inc

02/08/18 / #20180037644

Anti-il-33 antibodies, compositions, methods and uses thereof

. . The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to il-33, as well as uses, and associated methods thereof.. . ... Pfizer Inc

02/08/18 / #20180037575

Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.. . ... Pfizer Inc

01/25/18 / #20180022783

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride. ... Pfizer Inc

01/11/18 / #20180011103

Circulating tumor cell assay

Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (igf-1r) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. ... Pfizer Inc

01/04/18 / #20180002428

Anti-cxcr4 antibodies and antibody-drug conjugates

. . The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (cxcr4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. ... Pfizer Inc

01/04/18 / #20180002330

Methyoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof

The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.. . ... Pfizer Inc

01/04/18 / #20180000933

Stable aqueous anti-vascular endothelial growth factor (vegf) antibody formulation

The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. ... Pfizer Inc

01/04/18 / #20180000923

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride. ... Pfizer Inc

01/04/18 / #20180000922

Immunogenic compositions for use in pneumococcal vaccines

An object of the present invention is to provide immunogenic compositions for protection against s. Pneumoniae, in particular against s. ... Pfizer Inc

01/04/18 / #20180000885

Therapeutic nanoparticles with high molecular weight copolymers

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kda to about 90 kda or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kda to about 90 kda.. ... Pfizer Inc

12/21/17 / #20170360935

Formulations of a pi3k/mtor-inhibitor for intravenous administration

. . . . The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.. ... Pfizer Inc

12/21/17 / #20170360929

Stable aqueous antibody formulation for anti tnf alpha antibodies

The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation comprising methionine and its pharmaceutical preparation and use. ... Pfizer Inc

11/23/17 / #20170333535

Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

. . Compositions are provided comprising recombinant variants of the human clotting factor xa. Such compositions include a wide variety of isoforms and post-translational modifications of fxa and are useful for treating subjects in need of hemostasis.. ... Pfizer Inc

11/09/17 / #20170319479

Enhanced stability of novel liquid compositions

. . The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.. . ... Pfizer Inc

10/26/17 / #20170306051

Treatment with anti-pcsk9 antibodies

. . The present invention relates to therapeutic dosing regimens utilizing a dose reduction strategy for treating disorders characterized by marked elevations of low density protein cholesterol (ldl-c) in the plasma of a patient. The subject therapeutic dosing regimens involve delivering as a single administration or plurality of administrations of an anti-proprotein convertase subtilisin kexin type 9 (pcsk9) antagonist antibody as an initial dose of at least about 100 mg, and delivering as a single administration or plurality of administrations at a subsequent dose in an amount that is about the same as the initial dose, or at least half the initial dose after the patient has a ldl-c level at or below about 25, 20, 15 or 10 mg/dl, preferably at or below 10 mg/dl.. ... Pfizer Inc

10/26/17 / #20170305857

N-acylpiperidine ether tropomyosin-related kinase inhibitors

The present invention relates to compounds of formula (i) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as trk antagonists.. . ... Pfizer Inc

10/26/17 / #20170304262

Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease

The present invention relates to certain sglt-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (ckd). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.. ... Pfizer Inc

10/05/17 / #20170283393

Bruton's tyrosine kinase inhibitors

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Methods for the preparation of the compounds are disclosed. ... Pfizer Inc

10/05/17 / #20170281586

Solid molecular dispersion of fesoterodine hydrogen fumarate and polymeric binder

The present invention relates to solid molecular dispersion of fesoterodine hydrogen fumarate and a polymeric binder. The invention also relates to an inert core bead or particle which is coated with said solid molecular dispersion and to pharmaceutical formulations comprising such coated beads or particles.. ... Pfizer Inc

09/28/17 / #20170275366

Egfrviii specific chimeric antigen receptor for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an egfrviii monoclonal antibody, conferring specific immunity against egfrviii positive cells. The tcr ko engineered immune cells endowed with such cars are particularly suited for treating lung cancer, anal cancers and glioblastoma multiforme.. ... Pfizer Inc

09/28/17 / #20170275275

Benzenesulfonamides useful as sodium channel inhibitors

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide nav1.7 inhibitors of formula (i), or a pharmaceutically acceptable salt thereof, wherein x, r1, r2, r3a, r3b and r4 are as defined in the description. ... Pfizer Inc

09/28/17 / #20170275257

2-thiopyrimidinones

Myeloperoxidase inhibitor, pharmaceutical compositions containing the inhibitor and the use of the inhibitor to treat, for example, cardiovascular conditions.. . ... Pfizer Inc

09/28/17 / #20170273953

Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole

The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.. ... Pfizer Inc

09/21/17 / #20170266293

Methods of treating cancers with therapeutic nanoparticles

The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles.. . ... Pfizer Inc

09/21/17 / #20170266187

Pemetrexed polymeric nanoparticles and methods of making and using same

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.. ... Pfizer Inc

09/07/17 / #20170252352

Methods of use and combinations

The present invention relates to a compound of formula 1, 2 or 3: i ii iii wherein a is n or —cr0—, where r0 is hydrogen, c1-c6 linear or branched chain alkyl, etc., z is —cre—, or, —n—, where re is hydrogen, c1-c6 linear or branched chain alkyl, etc.; r1 is hydrogen, c1-c6 linear or branched chain alkyl, etc.; r2 are independently hydrogen or c1-c6 linear or branched chain alkyl; r3 and r4 are independently hydrogen, c1c6 linear or branched chain alkyl, etc.; r5 and r6 are independently hydrogen or c1-c6 linear or branched chain alkyl, etc.; r8 is hydrogen, c1-c6 linear or branched chain alkyl, etc.; r9 and r10 are independently hydrogen or c1-c6 linear or branched chain alkyl, etc.; q is —co—, —(ch2)q—, —(chrs)q—, or —(crsrt)q—, where rs and rt are independently c1-c6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to combinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.. . ... Pfizer Inc

08/31/17 / #20170247460

Anti-il-7r antibody compositions

. . The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a high concentration antibody formulation and its pharmaceutical preparation and use. ... Pfizer Inc

08/31/17 / #20170247372

Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting janus kinase (jak). ... Pfizer Inc

08/17/17 / #20170233390

Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof

. . . . . . The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.. . ... Pfizer Inc

08/17/17 / #20170233371

Rorc2 inhibitors and methods of use thereof

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.. . ... Pfizer Inc

08/10/17 / #20170226172

Fgf23 fusion proteins

Disclosed herein are fgf23 c-tail fusion proteins, pharmaceutical compositions comprising the fgf23 c-tail fusion proteins, and methods of treatment using the fgf23 c-tail fusion proteins. This application discloses fusion proteins comprising a fgf-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 vitd levels. ... Pfizer Inc

08/10/17 / #20170224804

Glycoconjugation processes and compositions

The invention provides etec linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (etec) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.. . ... Pfizer Inc

08/10/17 / #20170224620

Therapeutic nanoparticles having egfr ligands and methods of making and using same

Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—egfr ligand conjugate, wherein the egfr ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.. . ... Pfizer Inc

08/03/17 / #20170216452

Antibodies and antibody fragments for site-specific conjugation

. . The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.. . ... Pfizer Inc

08/03/17 / #20170216373

Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin

The present invention relates to compositions comprising probiotic and prebiotic components, mineral salts, lactoferrin, and possibly saccharomycetes, which perform correct, effective colonisation of the probiotic components administered, with enteric consequences which involve maintaining and/or restoring intestinal health and preventing the consequences of common dysbioses of the digestive tract caused by stress, incorrect dietary habits and antibiotic treatments. Said compositions also have a concomitant anti-inflammatory and immunomodulating action.. ... Pfizer Inc

08/03/17 / #20170215553

Dual-ended lip balm container

A three to six sided lip balm applicator of the present invention comprises a cap, a liner, and a base, having engagement assemblies for engaging the cap to the liner, the liner to the base, and a base from one lip balm applicator to an equivalent base from another lip balm applicator to form a lip balm container. The base comprises a partition with stabilizers which emerge from the partition and extend radially toward and overhang an aperture in the partition. ... Pfizer Inc

08/03/17 / #20170215552

Dual-ended lip balm container

A three to six sided lip balm applicator of the present invention comprises a cap, a liner, and a base, having engagement assemblies for engaging the cap to the liner, the liner to the base, and a base from one lip balm applicator to an equivalent base from another lip balm applicator to form a lip balm container. The base comprises a partition with stabilizers which emerge from the partition and extend radially toward and overhang an aperture in the partition. ... Pfizer Inc

07/27/17 / #20170210812

Antibodies specific for epidermal growth factor receptor variant iii and their uses

The present invention provides antibodies that specifically bind to egfrviii (epidermal growth factor receptor variant iii). The invention further provides bispecific antibodies that bind to egfrviii and another antigen (e.g., cd3) as well as antibody conjugates (e.g., antibody-drug-conjugates). ... Pfizer Inc

07/27/17 / #20170210811

Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

The invention provides chimeric antigen receptors (cars) that specifically bind to egfrviii (epidermal growth factor receptor variant iii). The invention further relates to engineered immune cells comprising such cars, car-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. ... Pfizer Inc

07/27/17 / #20170209374

Methods of controlling the morphology of polymeric nanoparticles

The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.. . ... Pfizer Inc

07/20/17 / #20170202938

Cancer vaccines

. . The present disclosure provides (i) isolated immunogenic taa polypeptides (i.e., an immunogenic muc1 polypeptides, an immunogenic msln polypeptides, and an immunogenic tert polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic taa polypeptides, (iii) compositions comprising an immunogenic taa polypeptide or an isolated nucleic acid molecule encoding an immunogenic taa polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.. . ... Pfizer Inc

07/20/17 / #20170202825

Apixaban formulations

Compositions comprising crystalline apixaban particles having a d90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.. . ... Pfizer Inc

07/20/17 / #20170202824

Apixaban formulations

Compositions comprising crystalline apixaban particles having a d90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.. . ... Pfizer Inc

07/06/17 / #20170190663

Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid

. . . . Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and alzheimer's disease.. . ... Pfizer Inc

07/06/17 / #20170189368

Stable formulations for lyophilizing therapeutic particles

The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.. ... Pfizer Inc

06/29/17 / #20170184602

Cancer treatment

Diagnostic methods for predicting whether a human tumor is sensitive to treatment with axitinib, and methods of treating a human tumor are disclosed. The methods are based on measurement of cd68 polypeptide expression levels in a tissue sample from a tumor. ... Pfizer Inc

06/29/17 / #20170183328

Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.. . ... Pfizer Inc

06/29/17 / #20170182151

Rsv f protein mutants

The present disclosure relates to rsv f protein mutants, nucleic acids or vectors encoding a rsv f protein mutant, compositions comprising a rsv f protein mutant or nucleic acid, and uses of the rsv f protein mutants, nucleic acids or vectors, and compositions.. . ... Pfizer Inc

06/15/17 / #20170165284

Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr

. . . . Compounds of formula (a) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (asgpr) targeting agents.. . ... Pfizer Inc

06/01/17 / #20170151341

Site specific her2 antibody drug conjugates

. . . . The present invention provides site specific her2 antibody drug conjugates and methods for preparing and using the same.. . ... Pfizer Inc

06/01/17 / #20170151181

Methods of treating cancers with therapeutic nanoparticles

The present disclosure relates in part to methods of treating cancers having a mutation in a ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.. . ... Pfizer Inc

05/11/17 / #20170128380

Targeted therapeutic nanoparticles and methods of making and using same

Described herein are polymeric nanoparticles that include a therapeutic agent, and methods of making and using such therapeutic nanoparticles. In some embodiments, the contemplated nanoparticles may include an excipient.. ... Pfizer Inc

05/04/17 / #20170119672

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.. ... Pfizer Inc

04/13/17 / #20170100467

Pcsk9 vaccine

. . The present invention relates to the provision of novel immunogens comprising an antigenic pcsk9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of pcsk9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.. ... Pfizer Inc

03/16/17 / #20170073428

Tissue factor pathway inhibitor antibodies and uses thereof

. . . . . . . . The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind tfpi and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.. ... Pfizer Inc

03/16/17 / #20170073395

Humanized antibodies

Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (cdrs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.. ... Pfizer Inc

03/16/17 / #20170073338

Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile

This invention relates to a novel crystalline form of 6-[(4r)-4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile which is useful as a selective androgen receptor modulator (sarm), and to compositions thereof and suitable processes for the preparation thereof.. . ... Pfizer Inc

03/09/17 / #20170067882

Physiologically-relevant affinity measurements in vitro with backscattering interferometry

Disclosed herein are improved optical detection methods comprising interferometric detection systems and methods of detecting a binding interaction between a sample comprising uncultured tissue homogenate and an analyte, together with various applications of the disclosed techniques. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.. ... Pfizer Inc

02/23/17 / #20170049709

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

. . . . The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer. Other aspects include methods of making and using such nanoparticles.. ... Pfizer Inc

02/16/17 / #20170044174

Heterocyclic compounds and their use as dopamine d1 ligands

The present invention provides, in part, compounds of formula (i): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, parkinson's disease, anxiety, and depression.. . ... Pfizer Inc

02/16/17 / #20170043033

Antibody-drug conjugates with high drug loading

The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (dar) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the dar is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.. ... Pfizer Inc

02/16/17 / #20170042828

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.. ... Pfizer Inc

02/09/17 / #20170037053

Heteroaromatic compounds and their use as dopamine d1 ligands

The present invention provides, in part, compounds of formula (i) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, parkinson's disease, anxiety, and depression.. . ... Pfizer Inc

02/09/17 / #20170037049

Heteroaromatic compounds and their use as dopamine d1 ligands

The present invention provides, in part, compounds of formula (i): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, parkinson's disease, anxiety, and depression.. . ... Pfizer Inc

02/09/17 / #20170035694

Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 50 weight percent of a corticosteroid; and about 50 to about 99 weight percent biocompatible polymer.. ... Pfizer Inc

01/26/17 / #20170021006

Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

. . The present invention relates to new immunogenic compositions comprising conjugated streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a s. ... Pfizer Inc

01/19/17 / #20170014526

Anti-notch3 antibodies and antibody-drug conjugates

. . The present invention provides for anti-notch3 antibodies, anti-notch3 antibody-drug conjugates and methods for preparing and using the same.. . ... Pfizer Inc

01/19/17 / #20170014523

Spliceostatin analogs and methos for their preparation

The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.. . ... Pfizer Inc

01/12/17 / #20170007713

Immunogenic glycoprotein conjugates

. . The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-et linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (i): (i) wherein: a is a group (c═x)m wherein x is s or o and m is 0 or 1; b is a bond, o, or ch2; and when m is 0, b can also be (c═o); r is a c2-c16 alkylene, c2-c16 heteroakylene, nh—c(═o)—c2-c16 alkylene, or nh—c(═o)—c2-c16 heteroakylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from coor′ where r′ is selected from h, methyl, ethyl or propyl. ... Pfizer Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pfizer Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pfizer Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###